Foster Jonathan P. 4

4 · Moleculin Biotech, Inc. · Filed Nov 6, 2024

Form 4

Period: 2024-10-25

EVP & CFO

Transactions

Award
Stock option (right to buy)
2024-11-04+65,000→ 129,837 total
Exercise: $2.45Exp: 2034-11-04→ Common Stock (65,000 underlying)
Award
Restricted Stock Units
2024-11-04+82,500→ 212,337 total
→ Common Stock (82,500 underlying)
Award
Performance Based Restricted Stock Units
2024-10-25+19,180→ 231,517 total
Exp: 2033-12-29→ Common Stock (19,180 underlying)

Footnotes (5)

[F1]The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
[F2]Issued in connection with the reporting person's employment with the Company.
[F3]Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
[F4]The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
[F5]On December 29, 2023, the Board approved this performance based restricted stock unit, subject to shareholder approval of the stock plan. The performance based restricted stock units set forth in this table will vest only upon both (A) the approval of the Plan Amendment by the Company stockholders; and (B) the first of the following to occur: (a) a licensing transaction with a valuation, at the time, in excess of $150 million, which valuation shall be determined by the Board; (b) the filing of a new drug application; or (c) upon a Change in Control (as defined in the Plan), in each case subject to the respective executive officer's continued service with the Company at each such vesting date.

Documents

1 file